SCHEMBL3635833

SCHEMBL3635833

NC(Cc1conc1CO)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.44
USP2 O75604 2/20 0.44
CYP3A4 P08684 2/20 0.44
HSD17B10 Q99714 2/20 0.44
HIF1A Q16665 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
BLM P54132 2/20 0.44
PMP22 Q01453 2/20 0.44
KMT2A Q03164 2/20 0.44
RGS12 O14924 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
NFKB1 P19838 1/20 0.44
CASP1 P29466 1/20 0.44
BRCA1 P38398 1/20 0.44
THPO P40225 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9182148 0.80 GRIA1 (0.46) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL5678957 0.80 HSD17B10 (0.50) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL25357109 0.68 SLC7A5 (0.52) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL4815808 0.68 SLC7A5 (0.52) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL7924230 0.67 SLC7A5 (0.60) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL9066677 0.67 SLC7A5 (0.60) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL8085428 0.67 SLC7A5 (0.60) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL21067436 0.67 GRIA2 (0.49) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL13971424 0.65 SLC7A5 (0.69) PKMUSP2CYP3A4HSD17B10HIF1A
SCHEMBL9164980 0.65 SLC7A5 (0.69) PKMUSP2CYP3A4HSD17B10HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180333488-A1 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS APELLIS PHARMACEUTICALS, INC. 2018-11-22 US disclosed
EP-2979729-A2 COMPSTATIN ANALOGUES FOR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM Apellis Pharmaceuticals, Inc. (US) 2016-02-03 EP disclosed
US-20140050739-A1 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS APELLIS PHARMACEUTICALS, INC. (US) 2014-02-20 US disclosed
US-8580735-B2 Local complement inhibition for treatment of complement-mediated disorders APELLIS PHARMACEUTICALS, INC. (US) 2013-11-12 US disclosed
US-20100166862-A1 Local Complement Inhibition for Treatment of Complement-Mediated Disorders POTENTIA PHARMACEUTICALS, INC. (US) 2010-07-01 US disclosed
EP-2148691-A2 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS Potentia Pharmaceuticals, Inc. (US) 2010-02-03 EP disclosed
WO-2008097525-A2 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS POTENTIA PHARMACEUTICALS, INC. (US) 2008-08-14 WO disclosed